VeriSIM Life December Newsletter
VeriSIM Life
Introducing BIOiSIM, an AI-driven drug development engine designed to de-risk and inform R&D decision-making.
We have several exciting developments to share as we approach the end of 2024, including VeriSIM Life's platform once again winning “Predictive Analytics Solution of the Year” in the BioTech Breakthrough Awards. Meanwhile, Dr. Jo Varshney has continued making significant contributions to the field, speaking at the UBS Tech Conference panel "AI Saving Lives” and being invited to participate in San Francisco Business Times’ Bizwomen Mentoring Monday. Looking ahead to January, the VeriSIM Life team is excited to engage with peers and potential partners at the JPM Healthcare Conference. We invite you to meet with us to explore how our BIOiSIM platform can transform your drug development pipeline by accurately predicting clinical trial outcomes!
VeriSIM Life wins BioTech Breakthrough Award for Third Year
VeriSIM Life was excited to announce that its platform has once again been named "Predictive Analytics Solution of the Year" by the 2024 BioTech Breakthrough Awards. The company was first recognized in the same category in 2022, then again in 2023. The awards program is conducted by BioTech Breakthrough, a leading independent marketing intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe. VeriSIM Life was recognized for its AtlasGEN Novel Drug Designer, which combines generative AI chemical discovery with biological validation to dramatically compress drug candidate selection and reduce costly experimental research, while increasing the likelihood of clinical success.
Meet with Us at the JPM Healthcare Conference
Attending the JPM Healthcare Conference in January? Our team will be available throughout the conference to meet with you and show you how we can help you expand your pipeline and get your next drug to market faster. We’d love to talk to you more about BIOiSIM, our AI platform that accurately predicts clinical trial outcomes. We use our platform to develop drug winners likely to succeed in clinical trials, and we’re backed by leading investors including Intel Capital, Mayo Clinic Ventures, Morpheus Ventures and others. Let’s meet to discuss how we can help accelerate your next breakthrough, significantly reducing the time and cost of early stage development.
领英推荐
Dr. Jo Varshney in UBS Tech Conference Panel “AI Saving Lives Panel”
CEO & Founder Dr. Varshney was excited to be a speaker at the UBS Tech Conference panel, “AI Saving Lives.” Topics discussed included how AI can improve healthcare delivery/patient outcomes, ethical considerations around the use of AI for handling patient data, strategies to maintain a competitive edge in the rapidly evolving AI landscape and more. It was a great opportunity to discuss these critical conversation points, as well as to network with other industry leaders.?
Dr. Jo Varshney at San Francisco Business Times Mentoring Monday
?Dr. Jo Varshney is thrilled to be included as a leader at the San Francisco Business Times Bizwomen #MentoringMonday event in February featuring the region’s top businesswomen sharing their secrets to success. Designed for busy professionals, the speed-mentoring sessions promote a supportive atmosphere to build connections &? receive valuable feedback and help local businesswomen advance their careers with guidance from leaders shaping the local business community.
What We’re Reading: Onyx Newsroom
?“There is a way to merge knowledge and AI, to be capital efficient and come up with meaningful outcomes. We call it the hybrid AI approach and that’s encapsulated in our platform BIOiSIM,” says Dr. Jo Varshney in this Onyx Newsroom article. “I've been engaged with translatability research for so long, but now it's more than a trend… (Top companies) want these solutions.”